Market Overview :
The
overactive bladder treatment market includes various therapies, namely,
anticholinergics, mirabegron, BOTOX, and neurostimulation used to treat the
sudden, involuntary contraction of the muscle in the urinary bladder wall
leading to urinary urgency, frequency, nocturia, and urge-incontinence.
The global market is projected to be valued at USD 3.63
Billion in 2017 and is expected to grow at a CAGR of 2.9% during the forecast
period to reach to USD 4.19 Billion by 2022.
The major players
in the global overactive bladder treatment market are :
Astellas Pharma, Inc. (Japan),
Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Allergan,
Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International
plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France),
Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical,
Inc. (U.S.).
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219938791
Geographically, the global market is segmented into
the U.S., Europe, Asia-Pacific, and the Rest of the World.In 2016, the U.S.
dominated the market and this is primarily attributed to its well-established
healthcare industry with favorable reimbursement of overactive bladder
treatment, growing prevalence of the disease with rising age, and the presence
of major players. The Rest of Asia-Pacific region is expected to witness the
highest CAGR during the forecast period owing to rising prevalence of bladder
overactivity, increasing geriatric population, rising healthcare expenditure, and
growing awareness on overactive bladder.
Comments
Post a Comment